

natureOUTLOOK

ANTIBIOTICS

1 May 2014 / Vol 509 / Issue No 7498



Cover art: Nik Spencer

Editorial

Herb Brody,
Mike May,
Michelle Grayson,
Tony Scully, Nick
Haines, Leonora
Dawson-Bowling

Art & Design

Wes Fernandes,
Alisdair Macdonald,
Andrea Duffy

Production

Karl Smart, Ian Pope,
Christopher Clough

Sponsorship

Janice Stevenson,
Yvette Smith,
Reya Silao

Marketing

Elena Woodstock,
Steven Hurst

Project Manager

Christian Manco

Art Director

Kelly Buckheit Krause

Publisher

Richard Hughes

Magazine Editor

Rosie Mestel

Editor-in-Chief

Philip Campbell

In the United States in the 1960s, a visit to the doctor usually entailed getting a shot of penicillin. It seemed that anything from hangnails to headaches called for an antibiotic “just in case”. At the same time, most cows and pigs on even small farms received antibiotics regularly whether they were needed or not. With such carefree prescribing, we cannot be surprised that we face big problems with antibiotic resistance today. It will take the combined efforts of academic researchers, pharmaceutical scientists and government officials, as well as the public, to fight the growing danger of untreatable bacterial diseases.

Promising approaches are being developed, however. For instance, industry and government are forming partnerships to develop new antibiotics (page S4), and researchers are seeking a better understanding of the mechanisms that drive bacterial resistance (S6). Sometimes — as with phage therapy (S9) — moving forwards means returning to yesterday’s treatments. Other scientists are exploring entirely new sources of antibiotics, from building nano-size structures to trawling the oceans for useful organisms (S10). Natural products collected through such searches can be chemically modified to attack a specific target (S13).

Addressing the growing health-care challenge will require more than new drugs, however. Advanced diagnostics will be crucial, from assessing environmental sources of potential infections to reducing the waste of antibiotics (S14). And governments and social organizations around the world are working to reduce the overuse of antibiotics in agriculture and medicine (S16). All this means that future generations will have a very different experience of antibiotics.

We acknowledge the financial support of Roche in producing this Outlook. As always, *Nature* has full responsibility for all editorial content.

Mike May

Contributing Editor

CONTENTS

S2 ANTIBIOTIC RESISTANCE

An infectious arms race

The constant quest for drugs that work

S4 DRUG DEVELOPMENT

Time for teamwork

Government and industry join forces

S6 MICROBIOLOGY

Resistance fighters

Seeking weak spots in bacterial evolution

S9 PERSPECTIVE

The age of the phage

Shigenobu Matsuzaki and colleagues call for the return of bacteria-killing viruses

S10 DRUG DISCOVERY

Leaving no stone unturned

The global search for new antibiotics

S13 PERSPECTIVE

Synthetic biology revives antibiotics

Re-engineering natural products will create new drugs, says Gerard Wright

S14 DIAGNOSTICS

Detection drives defence

Faster diagnosis could slow antibiotic resistance

S16 PUBLIC HEALTH

The politics of antibiotics

Overuse is creating a tragedy

COLLECTION

S18 Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome
Sheetal R. Modi et al.

S22 Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomicin against methicillin-resistant *Staphylococcus epidermidis*
Li-guang Liu et al.

S26 Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance
Adam C. Palmer and Roy Kishony

S32 ND4BB: addressing the antimicrobial resistance crisis
John H. Rex

S34 Persisters, persistent infections and the Yin–Yang model
Ying Zhang

Nature Outlooks are sponsored supplements that aim to stimulate interest and debate around a subject of interest to the sponsor, while satisfying the editorial values of *Nature* and our readers’ expectations. The boundaries of sponsor involvement are clearly delineated in the *Nature Outlook* Editorial guidelines available at http://www.nature.com/advertising/resources/pdf/outlook_guidelines.pdf

CITING THE OUTLOOK

Cite as a supplement to *Nature*, for example, *Nature* Vol XXX, No. XXXX Suppl, Sxx–Sxx (2014). To cite previously published articles from the collection, please use the original citation, which can be found at the start of each article.

VISIT THE OUTLOOK ONLINE

The *Nature Outlook Antibiotics* supplement can be found at <http://www.nature.com/nature/outlook/antibiotics>

All featured articles will be freely available for 6 months.

SUBSCRIPTIONS AND CUSTOMER SERVICES

For UK/Europe (excluding Japan): Nature Publishing Group, Subscriptions, Brunel Road, Basingstoke, Hants, RG21 6XS, UK. Tel: +44 (0) 1256 329242. Subscriptions and customer services for Americas – including Canada, Latin America and the Caribbean: Nature Publishing Group, 75 Varick St, 9th floor, New York, NY 10013-1917, USA. Tel: +1 866 363 7860 (US/Canada) or +1 212 726 9223 (outside US/Canada). Japan/China/Korea: Nature Publishing Group — Asia-Pacific, Chiyoda Building 5-6th Floor, 2-37 Ichigaya Tamachi, Shinjuku-ku, Tokyo, 162-0843, Japan. Tel: +81 3 3267 8751.

CUSTOMER SERVICES

Feedback@nature.com
Copyright © 2014 Nature Publishing Group